Kidney Cancer Panel - Disclosures
|
Panel Member
|
Neeraj Agarwal MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Hilary Bagshaw MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Michael Baine MD, PhD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Marian Birkeland PhD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Nicole Blankenhorn |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Maria Carlo MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Toni Choueiri MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Brian Costello MD, MS |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Ithaar Derweesh MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Arpita Desai MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Tanya Fischer MEd, MLIS |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Yasser Ged MBBS |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Saby George MD, FACP |
|
Grant/Research Support
|
| AVEO Pharmaceuticals, Inc. | Bayer HealthCare | Bristol Myers Squibb | Eisai Inc. | Exelixis Inc. | Gilead Sciences, Inc. | Merck & Co., Inc. | Novartis Pharmaceuticals Corporation |
|
Date Completed
|
03/31/2025 |
|
Panel Member
|
Nikhil Gopal MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
John Gore MD, MS |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Kristina Gregory MSN, RN |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Andrew Gunn MD |
|
Grant/Research Support
|
| Penumbra | Varian |
|
Date Completed
|
03/10/2025 |
|
Panel Member
|
Naomi Haas MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Evelyn Handel PharmD, BCOP, BCPS |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Erin Hesler |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Anne Holbrook PharmD, BCOP |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Angela Jia MD, PhD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Eric Jonasch MD |
|
Grant/Research Support
|
| AbbVie, Inc. | AVEO Pharmaceuticals, Inc. | Bristol Myers Squibb | Corvus | Merck & Co., Inc. | NiKang | Telix |
|
Date Completed
|
07/30/2024 |
|
Panel Member
|
Samuel Kaffenberger MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Payal Kapur MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Jennifer King MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Christos Kyriakopoulos MD |
|
Grant/Research Support
|
| AstraZeneca Pharmaceuticals LP | Bristol Myers Squibb | EMD Serono | ESSA Pharma | Gilead Sciences, Inc. | Incyte Corporation | Madison Vaccines, Inc. | Merck & Co., Inc. | Pionyr Immunopharma | sanofi-aventis U.S. |
|
Date Completed
|
06/24/2024 |
|
Panel Member
|
Elaine Lam MD |
|
Grant/Research Support
|
| Arrowhead | Astellas Pharma US, Inc. | AstraZeneca Pharmaceuticals LP | Biosplice | Bristol Myers Squibb | Exelixis Inc. | Flatiron Health, Inc. | Forma Therapeutics | Genentech, Inc. | HiberCell | Merck & Co., Inc. | OnQuality | Pfizer Inc. | Promontory Therapeutics (formerly Phosplatin) | Roche Laboratories, Inc. |
|
Date Completed
|
04/25/2025 |
|
Panel Member
|
Primo Lara, Jr. MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Clayton Lau MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Bryan Lewis JD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
David Madoff MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Brandon Manley MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
M. Dror Michaelson MD, PhD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Amir Mortazavi MD |
|
Grant/Research Support
|
| Astellas Pharma US, Inc. | Bristol Myers Squibb | Genentech, Inc. | GSK | Merck & Co., Inc. | NiKang Therapeutics, Inc. | Novartis Pharmaceuticals Corporation | Roche Laboratories, Inc. | SeaGen |
|
Date Completed
|
05/05/2025 |
|
Panel Member
|
Robert Motzer MD |
|
Grant/Research Support
|
| Bristol Myers Squibb | Eisai Inc. | Exelixis Inc. | Merck & Co., Inc. | Pfizer Inc. |
|
Date Completed
|
03/23/2025 |
|
Panel Member
|
Svitlana Ostanina PhD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Kent Perry, Jr. MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Donna Powell DHSc, CMD, RT(T) |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Sundhar Ramalingam MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Brian Rini MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Ryan Schonfeld BA |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Brian Shuch MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
MaryElizabeth Stein PhD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Bettyanne Sunderland BSN, OCN |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Randy Sweis MD |
|
Equity Interest/Stock Options
|
| AbbVie, Inc. |
|
Grant/Research Support
|
| Ascendis | Astellas Pharma US, Inc. | Bayer HealthCare | Bristol Myers Squibb | Cullinan | Gilead Sciences, Inc. | Immunocore | Loxo-Lilly | Merck & Co., Inc. | Mirati | Moderna | Pionyr | Pyxis Oncology | Scholar Rock |
|
Intellectual Property Rights
|
| Patent: Neoantigens in Cancer, PCT/US2020/031357 |
|
Date Completed
|
06/24/2024 |
|
Panel Member
|
Lewis Thomas MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
|
Panel Member
|
Matthew Zibelman MD |
| The faculty listed above have no relevant financial relationship(s) with ineligible companies to disclose. |
